GlaxoSmithKline plc Stock LIQUIDNET SYSTEMS
Stocks
GSK
GB0009252882
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-0.40% | - |
| 06-18 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
| 06-18 | The Gulf Gives, the Fed Takes | |
| Market Cap | 76.77B 102B 88.53B 81.61B 144B 9,576B 145B 971B 377B 4,719B 381B 373B 16,357B | P/E 2026 * |
12.3x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 91.02B 120B 105B 96.77B 170B 11,354B 171B 1,151B 447B 5,596B 452B 443B 19,394B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.29% | Yield 2026 * |
3.64% | Yield 2027 * | 3.81% |
Last Transcript: GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.40% | - | - | 105B | |
| -1.21% | -5.37% | +39.94% | +145.38% | 992B | |
| -2.48% | -4.17% | +51.52% | +39.07% | 564B | |
| -2.14% | -3.68% | +16.71% | +56.15% | 391B | |
| -1.18% | +0.25% | +25.86% | +16.53% | 330B | |
| -2.36% | -3.12% | +24.71% | +11.59% | 280B | |
| -2.45% | -2.88% | +24.29% | +30.06% | 279B | |
| -1.91% | -0.87% | -41.95% | -49.25% | 196B | |
| -1.19% | -4.65% | +16.56% | +47.00% | 184B | |
| -1.35% | -1.68% | +14.59% | +56.94% | 156B | |
| Average | -1.63% | -1.98% | +19.14% | +39.27% | 374.58B | |
| Weighted average by Cap. | -1.72% | -2.88% | +28.03% | +63.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.78B 44.72B 38.96B 35.92B 63.2B 4,214B 63.65B 427B 166B 2,077B 168B 164B 7,199B | 35.48B 46.96B 40.92B 37.72B 66.37B 4,426B 66.84B 449B 174B 2,181B 176B 172B 7,560B |
| Net income | 6.27B 8.29B 7.23B 6.66B 11.72B 782B 11.81B 79.26B 30.78B 385B 31.13B 30.47B 1,335B | 6.67B 8.83B 7.69B 7.09B 12.48B 832B 12.56B 84.36B 32.76B 410B 33.14B 32.43B 1,421B |
| Net Debt | 14.25B 18.86B 16.44B 15.15B 26.66B 1,778B 26.85B 180B 70.01B 876B 70.81B 69.29B 3,037B | 11.19B 14.81B 12.9B 11.9B 20.93B 1,396B 21.08B 142B 54.96B 688B 55.59B 54.4B 2,384B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
